Following the lifting of a regulatory hold late last year, a U.S. clinical trial testing LTI-03, an inhaled therapy for people with idiopathic pulmonary fibrosis (IPF), is now fully underway. Treatment developer Rein Therapeutics announced that dosing has started in the Phase 2 clinical trial, which aims to assess the…
News
Regulatory authorities in both the U.S. and the European Union have granted orphan drug status to deupirfenidone (LYT-100), an oral therapy Puretech Health is developing to treat idiopathic pulmonary fibrosis (IPF). This designation aims to provide extra economic incentives to companies that invest in developing medications for rare…
Mutations in the ACVRL1 gene may play a role in the development of idiopathic pulmonary fibrosis (IPF), and targeting the gene — until now, little noted, according to researchers — could potentially lead to new treatments for the respiratory disease, a study suggests. Additionally, according to the scientists, the study…
Treatment with Esbriet (pirfenidone) reduces the risk of irregular heartbeat by nearly 90% in adults with idiopathic pulmonary fibrosis (IPF), according to a new study. Use of the approved IPF drug also eased the worsening of atrial arrhythmias — irregular heartbeats originating in the upper chambers of the heart —…
New Phase 2a clinical trial data suggest that treatment with GRI-0621, an experimental oral therapy from GRI Bio, altered the activity of genes linked to inflammation and lung scarring (fibrosis) in adults with idiopathic pulmonary fibrosis (IPF). The therapy was also associated with increased activity of genes involved…
Activity levels of four genes linked to the Notch signaling pathway — which helps regulate cell growth, tissue repair, and immune responses in the body — may serve as blood-based biomarkers that could aid in the early diagnosis of idiopathic pulmonary fibrosis (IPF). Those are the findings of a…
The European Medicines Agency (EMA) has awarded orphan drug designation to Rein Therapeutics’ lead drug candidate, LTI-03, which is being developed to help preserve lung function in people with idiopathic pulmonary fibrosis (IPF). The designation follows a positive opinion from the EMA’s Committee for Orphan Medicinal Products, which evaluates…
Treatment with the experimental oral therapy GRI-0621 modulated immune cell activity in adults with idiopathic pulmonary fibrosis (IPF) in an early Phase 2a clinical trial, according to new data announced by its developer, Gri Bio. Data from the Phase 2a study (NCT06331624) broadly suggest that GRI-0621 is…
Individuals with lingering signs of pulmonary fibrosis (PF) months after recovering from COVID-19 were found to be older and to have significantly lower levels than normal of beneficial gut bacteria, particularly Bifidobacterium and Blautia, a new study reports. In follow-up experiments, a mouse model of PF given supplements of…
The U.S. Food and Drug Administration (FDA) has approved Jascayd (nerandomilast), taken as oral tablets, as a treatment for adults with progressive pulmonary fibrosis (PPF), in which lung scarring worsens over time. “Progressive pulmonary fibrosis is a life-threatening condition with a high unmet medical need. The U.S. approval…
